Old Drugs and New Targets as an Outlook for the Treatment of Tuberculosis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F18%3A10383134" target="_blank" >RIV/00216208:11160/18:10383134 - isvavai.cz</a>

Result on the web

<a href="http://www.eurekaselect.com/155754/article" target="_blank" >http://www.eurekaselect.com/155754/article</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/0929867324666170920154325" target="_blank" >10.2174/0929867324666170920154325</a>

Result language

angličtina

Original language name

Old Drugs and New Targets as an Outlook for the Treatment of Tuberculosis

Original language description

Background: Despite of the globally positive trends in the epidemiology of tuberculosis, the increasing rates of drug-resistant strains are urging to introduce new antituberculars into clinical practice. Development of a new chemical entity from hit to marketed drug is an extremely time and resources consuming process with uncertain outcome. Repurposing of clinically used drugs can be a cheaper alternative to develop new drugs effective in the treatment of tuberculosis. Objective: To extract the latest information on new mechanisms of action described or proposed for clinically used antitubercular drugs. To identify drugs from various pharmacodynamic groups as candidates for repurposing to become effective in combatting tuberculosis. Attention will be paid to elucidate the connection between repurposed drugs and new antituberculars in clinical practice or in clinical trials. Methods: Scientific databases were searched for the keywords. Results: We reviewed the latest aspects of usage and new mechanisms of action for both first-line and second-line antitubercular drugs in clinical practice. Further, we found that surprisingly large number of clinically used drugs from various pharmacodynamic groups have potential to be used in the treatment of tuberculosis, including antimicrobial drugs not typically used against tuberculosis, statins, CNS drugs (tricyclic phenothiazines, antidepressants, anticonvulsants), non-steroidal anti-inflammatory drugs, kinase inhibitors, and others (metformin, disulfiram, verapamil, lansoprazole). Repurposed drugs may become effective antituberculars, acting either by direct effects on mycobacteria or as adjunct, host-directed therapy. Conclusion: In this review, we showed that proper research of old drugs is a very efficient tool to develop new antituberculars.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

<a href="/en/project/GJ17-27514Y" target="_blank" >GJ17-27514Y: Peptide Drug Delivery Systems Targeting Macrophages for Antimycobacterial Active Compounds</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Current Medicinal Chemistry

ISSN

0929-8673

e-ISSN

—

Volume of the periodical

25

Issue of the periodical within the volume

38

Country of publishing house

NL - THE KINGDOM OF THE NETHERLANDS

Number of pages

26

Pages from-to

5142-5167

UT code for WoS article

000455988100008

EID of the result in the Scopus database

2-s2.0-85059532933